SynthesisThe European journal of health economics : HEPAC : health economics in prevention and care2018
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.
Synthesis in The European journal of health economics : HEPAC : health economics in prevention and care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Selection and Prioritization of Medical Devices for HTA Evaluation: A Systematic Review of Existing Approaches.Applied health economics and health policy · 2025Pooled it
- Institutional Priority-Setting for Novel Drugs and Therapeutics: A Qualitative Systematic Review.International journal of health policy and management · 2024Pooled it
- HTA Barriers for Conditional Approval Drugs.PharmacoEconomics · 2023Pooled it
- A systematic review of the early dialogue frameworks used within health technology assessment and their actual adoption from HTA agencies.Frontiers in public health · 2022Pooled it
- Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Pooled it
- Cost-effectiveness analysis of the MYO ArmbandJournal of neuroengineering and rehabilitation · 2025Trial
- Early access to medicines in Spain: a retrospective hospital study with a proposal for a regulatory change.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Addressing the Global Disparities in Access to Treatment in Spinal Muscular Atrophy.Muscle & nerve · 2026Review
- Value in app store metadata and user reviews: A dual perspective on quality of Parkinson's and dementia apps.PLOS digital health · 2026Article
- The Post-Authorisation Maze: Mapping of European Pharmaceutical Market Access Pathways in the Early JCA Era.Journal of market access & health policy · 2026Article
- Pricing of innovative medicines and advanced therapies worldwide: an scoping review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Developing an early scientific advice framework for health technology assessment in Saudi Arabia: insights from global practices and expert consultations.Cost effectiveness and resource allocation : C/E · 2026Article
- Article
- Impact of Market Access Delays on Time to Patient Access: Multi-Country Comparative Analysis Assessing the First Commercial Launch Indications for Five Oncology Medicines Across Europe and Canada.Journal of market access & health policy · 2026Article
- Introducing an Expanded Value Framework in Health Technology Assessment of Vaccines.Journal of market access & health policy · 2026Article
- The Impact of Health Technology Assessment on Pharmaceutical Prices: Evidence from Germany.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Harnessing health economic evaluation for policy and practice.Communications medicine · 2026Review
- A Cross-Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real-World Evidence.Pharmacoepidemiology and drug safety · 2026Article
- Early viability assessment of a Business-to-Consumer (B2C) model for digital diabetes screening in Switzerland.BMC health services research · 2026Article
- A comparative analysis of health technology assessment decision-making for cancer drugs in Germany and England.Frontiers in public health · 2026Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAlthough health technology assessment (HTA) systems base their decision making process either on economic evaluations or comparative clinical benefit assessment, a central aim of recent approaches to value measurement, including value based assessment and pricing, points towards the incorporation of supplementary evidence and criteria that capture additional dimensions of value.
objectiveTo study the practices, processes and policies of value-assessment for new medicines across eight European countries and the role of HTA beyond economic evaluation and clinical benefit assessment.
methodsA systematic (peer review and grey) literature review was conducted using an analytical framework examining: (1) 'Responsibilities and structure of HTA agencies'; (2) 'Evidence and evaluation criteria considered in HTAs'; (3) 'Methods and techniques applied in HTAs'; and (4) 'Outcomes and implementation of HTAs'. Study countries were France, Germany, England, Sweden, Italy, Netherlands, Poland and Spain. Evidence from the literature was validated and updated through two rounds of feedback involving primary data collection from national experts.
resultsAll countries assess similar types of evidence; however, the specific criteria/endpoints used, their level of provision and requirement, and the way they are incorporated (e.g. explicitly vs. implicitly) varies across countries, with their relative importance remaining generally unknown. Incorporation of additional 'social value judgements' (beyond clinical benefit assessment) and economic evaluation could help explain heterogeneity in coverage recommendations and decision-making.
conclusionMore comprehensive and systematic assessment procedures characterised by increased transparency, in terms of selection of evaluation criteria, their importance and intensity of use, could lead to more rational evidence-based decision-making, possibly improving efficiency in resource allocation, while also raising public confidence and fairness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.